Biocom California Newsletter

What’s Inside: List of Drugs to Undergo Price Negotiations Announced; RayzeBio Plans to Go Public this Week; Executive Order on Domestic Manufacturing; and more.

What’s Inside: Novartis Acquires DTx Pharma; Nominate a Young Life Science Leader for the 2023 Catalyst Awards; Korea’s Minister of Health and Delegates Visit San Diego; Biocom California Hosts NCI SBIR Director; and more.

What’s Inside: Honoring Pride Month; Abbott and Dexcom Aim to Bring Continuous Glucose Monitoring to Millions; UPSIDE Foods Earns USDA Label for its Cultivated Meat; Water Rates to Increase in San Diego; and more.

What’s Inside: Biocom California Expands International Opportunities to South Korea; Celebrating National Women’s Health Week; Our Annual Advocacy Fly-In to D.C.; Total Rewards Survey Now Open; and more.

What’s Inside: Tune Into Our New Podcast; Top Stories in State and Local Politics; Celebrate Earth Day With Us; Gilead Launches Oncology Campaign; and more.

What’s Inside: Biggest Takeaways from Our Global Life Science Partnering & Investor Conference; Statement on Silicon Valley Bank; Rapport Therapeutics Launches with $100M; Ionis Pharmaceuticals Expands; and more.

What’s Inside: Announcing Our New Board Members; CIRM Elects Dr. Imbasciani as Chair; Gilead Receives $7.6M to Advance Health Equity in Breast Cancer; and more.

What’s Inside: Our Focus Areas for 2023; FDA Approvals for Ferring and Gilead; NIH Commits $4.8M for All of Us Genetic Research Program; California’s Drought is Likely to Persist Even After Heavy Rainfall; and more.

What’s Inside: Our 10 Most-Read Stories of 2022; Upside Foods Gets Safety Nod from FDA for Cell-Cultured Meat; UCSD Receives $20M Gift; Take this Year’s DE&I Survey; and more.

What’s Inside: IGD Simulation Lab with Illumina; The Latest in Sustainable Materials; Vir Presents Positive Data for HBV Therapies; Midterm Election Results; and more.